Date: Monday, December 10, 2007 from 1:30pm - 3:00pm EST
Session Type: Oral Session
Title: "SGX70393 Inhibits BCR-ABL & T315I In Vitro and In Vivo
and Completely Suppresses Resistance When Combined with
Nilotinib or Dasatinib."
Description: An oral presentation, coauthored with collaborators at the
Oregon Health & Science University Cancer Institute,
describes a proof of principle study demonstrating the
potential of combination targeted therapy for CML. SGX393
(also known as SGX70393) is a potent, selective
orally-bioavailable inhibitor of both wild type and major
drug resistant mutant forms of BCR-ABL, including the most
challenging T315I mutation.
"These two ASH presentations explain how SGX is using its
drug discovery platform to discover and optimize potent,
selective and orally-bioavailable inhibitors of important
oncology drug discovery targets," said Stephen Burley,
Chief Scientific Officer of SGX Pharmaceuticals.
"Moreover, the results obtained with our collaborators at
the Oregon Health & Science University Cancer Institute
demonstrate the potential of targeted combination therapy
for CML. A number of influential thought leaders believe
that effective management of newly-diagnosed CML will
depend on long-term treatment with multiple agents
possessing non-overlapping resistance profiles."
About the SGX BCR-ABL Program
SGX393 is an internally developed, orally-bioavailable, small molecule
inhibitor of the abnor
|SOURCE SGX Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved